Could your own fat cells save your dialysis access?

NCT ID NCT02808208

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether a patient's own fat-derived stem cells, applied during surgery, can prevent dialysis fistulas from failing. About 74 adults with advanced kidney disease will receive either stem cells or a placebo. The goal is to see if the treatment improves vein size and blood flow for dialysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient's own fat-derived stem cells
What this could lead to: If it works, this could point toward a way to keep dialysis fistulas working longer, reducing complications and hospital visits.
What could go wrong: This is a very early phase 1 trial with only 74 people, so it may not show clear benefit. Risks include infection or poor fistula function despite treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL DISEASE (ESRD) VASCULAR ACCESS COMPLICATION

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.